| 3.06 -0.06 (-1.92%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.79 | 1-year : | 4.08 |
| Resists | First : | 3.24 | Second : | 3.5 |
| Pivot price | 3.23  |
|||
| Supports | First : | 2.83 | Second : | 2.36 |
| MAs | MA(5) : | 3.18 |
MA(20) : | 3.21  |
| MA(100) : | 2.79 |
MA(250) : | 5.35 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 22.9 |
D(3) : | 35.7 |
| RSI | RSI(14): 43.9 |
|||
| 52-week | High : | 13.48 | Low : | 2.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NERV ] has closed above bottom band by 13.4%. Bollinger Bands are 60.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.13 - 3.15 | 3.15 - 3.16 |
| Low: | 2.99 - 3.02 | 3.02 - 3.04 |
| Close: | 3.03 - 3.06 | 3.06 - 3.09 |
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Sun, 21 Jul 2024
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com - Defense World
Mon, 06 May 2024
Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Thu, 22 Feb 2024
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates - Yahoo Finance
Fri, 19 May 2023
Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead - Seeking Alpha
Wed, 10 May 2023
Minerva Neurosciences Announces Update on its New Drug - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 22.2 (%) |
| Held by Institutions | 30.3 (%) |
| Shares Short | 15 (K) |
| Shares Short P.Month | 32 (K) |
| EPS | -4.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -5.24 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.7 |
| PEG Ratio | 0 |
| Price to Book value | -0.59 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|